Keyword Search
 
2017 | 2016
06/07/17

Aptevo Therapeutics Highlights Key Features of Its ADAPTIR™ Protein Therapeutic Platform at Two Industry Conferences

SEATTLE, June 07, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, announced today that aspects of its ADAPTIR™ protein therapeutic platform were showcased recently at the Americas Antibody Congress 2017 in San Diego, May 23-24, 2017, and at the 2017 Next Generation Protein Therapeutics Summit in San Diego, June 5-7, 2017. In a presentation entitled, “From the Bench to the Clinic...

Read More

05/12/17

Aptevo Therapeutics Reports First Quarter 2017 Financial Results

Expands ADAPTIR Portfolio and Announces New Bispecific Candidate; Presents Data at the 2016 PEPTALK Conference Showcasing Advantages of the ADAPTIR™ Platform SEATTLE, May 12, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today provided a business review and reported its financial results for the first quarter ended March 31, 2017. “Aptevo made important strides in early 2017 in both...

Read More

05/05/17

Aptevo Therapeutics Presents Detailed Overview of its Adaptir™ Protein Therapeutic Platform at the 13th Annual Pegs Summit

Key Advantages of the ADAPTIR Platform Showcased During the  ‘Bispecific Antibodies in Oncology’ Session SEATTLE, May 05, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, announced today that it presented information on the Company’s ADAPTIR™ protein therapeutic platform at the 13th Annual Protein Engineering (PEGS Summit) in Boston, May 1-4, 2017.  Dr. Peter Pavlik, Principal Sc...

Read More

04/10/17

Aptevo Therapeutics Presents New Clinical Data Evaluating the Safety and Efficacy of IXINITY in Children With Hemophilia B

Data Presented at the Hemostasis and Thrombosis Research Society 2017 Scientific Symposium SEATTLE, April 10, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the presentation of new clinical data evaluating the safety and efficacy of IXINITY® [Coagulation Factor IX (Recombinant)] in previously treated patients under 12 years of age with Hemophilia B.  The data suggest t...

Read More

04/03/17

Aptevo Therapeutics’ Next Generation ADAPTIR™ Bispecific Antibody Candidates Show Potent Immune Activation

New Preclinical Data Presented at the 2017 American Association for Cancer Research Annual Meeting Demonstrate Antibody-like Characteristics and Efficacy of Redirected T-Cell Cytotoxicity Therapeutic Approach Antibody-like Serum Half-life in Mice of up to 12.5 days – Significantly Longer than Other Bispecific Antibody Candidates in Development   SEATTLE, April 03, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and...

Read More

03/31/17

Aptevo Therapeutics Reports 2016 Financial Results and Provides Business Update

Advances Multiple Clinical and Preclinical Candidates Based on the Company’s  Novel ADAPTIR™ Protein Therapeutic Platform Achieves 30% Increase in Year-Over-Year Product Sales Revenue SEATTLE, March 31, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today reported its financial results for the year ended December 31, 2016 and provided an update on its commercial portfolio and pipeline...

Read More

03/15/17

Aptevo Therapeutics Announces New IXINITY Supply Available May 2017

Initial Bulk Drug Substance Batch Successfully Manufactured SEATTLE, March 15, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the successful manufacture of a recent bulk drug substance (BDS) batch of IXINITY® [Coagulation Factor IX (Recombinant)].  Consequently, Aptevo anticipates that new supply will be available beginning in May 2017, after the completion of routine fi...

Read More

03/14/17

Aptevo Therapeutics Expands Bispecific Antibody Portfolio

Preclinical Data on New Anti-CD123 ADAPTIR™ Bispecific Candidates to be Presented at the American Association for Cancer Research (AACR) 2017 Annual Meeting SEATTLE, March 14, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that preclinical data for new bispecific antibody candidates targeting CD123 and CD3 will be presented in a poster session at the 2017 Annual Meeting ...

Read More

03/06/17

Aptevo Therapeutics to Present at the 29th Annual ROTH Conference

SEATTLE, March 06, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 29th Annual ROTH Conference on Wednesday, March 15, 2017 at 10:30 AM PT at the Ritz Carlton, Laguna Niguel, California. A live audio webcast of the presentation can be accessed at www.aptevotherapeutics.com under the ‘Investors’ section of the website, under ‘Eve...

Read More

01/13/17

Aptevo Therapeutics Receives $20 Million Payment From Emergent BioSolutions

SEATTLE, Jan. 13, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has received a $20 million cash payment from Emergent BioSolutions pursuant to a promissory note granted as a result of the spin-off of Aptevo from Emergent, effective August 1, 2016. With the additional $20 million cash payment announced today, Emergent has provided a total of $65 million in cash...

Read More

01/12/17

Aptevo Therapeutics Presents Data on Its ADAPTIR™ Antibody Platform at the 16th Annual PEPTALK Conference

Preclinical Data Presented Show that ADAPTIR™ Platform Offers Unique Approach for Generating Bispecific Antibodies with Favorable Therapeutic Profile SEATTLE, Jan. 12, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that Dr. John Blankenship, a Lead Scientist at Aptevo, presented new data on the Company’s bispecific antibody program based on the ADAPTIR platform technolog...

Read More

01/04/17

Aptevo Therapeutics Resumes IXINITY Manufacturing; Anticipates Re-Entering the Market in the Second Quarter of 2017

SEATTLE, Jan. 04, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that it has resumed IXINITY® manufacturing operations and anticipates that new supply of IXINITY will be available beginning in the second quarter of 2017. Today’s announcement follows a Notice of Interruption in Manufacturing submitted by Aptevo to the Food and Drug Administration (FDA) and reported in t...

Read More